|
Overdosage & Contraindications
CONTRAINDICATIONS
WELLBUTRIN SR is contraindicated in patients with a seizure disorder. WELLBUTRIN SR is contraindicated in patients treated with ZYBAN ® (bupropion hydrochloride) Sustained-Release Tablets, or any other medications that contain bupropion because the incidence of seizure is dose dependent. WELLBUTRIN SR is contraindicated in patients with a current or prior diagnosis of bulimia or anorexia nervosa because of a higher incidence of seizures noted in patients treated for bulimia with the immediate-release formulation of bupropion. Text Continues Below
WELLBUTRIN SR is contraindicated in patients undergoing abrupt discontinuation of alcohol or sedatives (including benzodiazepines). The concurrent administration of WELLBUTRIN SR Tablets and a monoamine oxidase (MAO) inhibitor is contraindicated. At least 14 days should elapse between discontinuation of an MAO inhibitor and initiation of treatment with WELLBUTRIN SR Tablets. WELLBUTRIN SR is contraindicated in patients who have shown an allergic response to bupropion or the other ingredients that make up WELLBUTRIN SR Tablets. OVERDOSAGE Human Overdose Experience There has been very limited experience with overdosage of WELLBUTRIN SR Tablets; 3 cases were reported during clinical trials. One patient ingested 3,000 mg of WELLBUTRIN SR Tablets and vomited quickly after the overdose; the patient experienced blurred vision and lightheadedness. A second patient ingested a "handful" of WELLBUTRIN SR Tablets and experienced confusion, lethargy, nausea, jitteriness, and seizure. A third patient ingested 3,600 mg of WELLBUTRIN SR Tablets and a bottle of wine; the patient experienced nausea, visual hallucinations, and "grogginess." None of the patients experienced further sequelae. There has been extensive experience with overdosage of the immediate-release formulation of bupropion. Page: 1 | 2 | 3 | Next >>
|
.gif)
